Passive transfer of SARS-CoV-2 antibodies with platelet transfusions.
Sars-CoV-2
antibodies
covid-19
platelets
transfusion
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
07
01
2022
received:
19
08
2021
accepted:
21
01
2022
pubmed:
23
2
2022
medline:
8
4
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
Although over 5000 platelet transfusions occur daily in the United States, the presence of SARS-CoV-2 antibodies in platelet units is not commonly evaluated for. The effects of platelet transfusions with SARS-CoV-2 antibodies remain largely unknown. We evaluated single-donor (apheresis) platelet units for SARS-CoV-2 antibodies and determined if platelet transfusions passively transferred antibodies to seronegative recipients. We conducted a retrospective analysis as part of a quality assurance initiative during February to March 2021 at a tertiary referral academic center in suburban New York. Platelet units and platelet recipients were evaluated for the presence of SARS-CoV-2 antibodies using the DiaSorin LIASON SARS-CoV-2 S1/S2 IgG assay. There were 47 platelet recipients eligible for study inclusion. The primary outcome was the presence of SARS-CoV-2 spike protein IgG antibodies in the recipient's blood after platelet transfusion. Twenty-three patients received platelets with SARS-CoV-2 spike protein IgG antibodies; 13 recipients had detection of SARS-COV-2 antibodies (56.5%), and 10 recipients did not. The median antibody titer in the platelet units given to the group with passive antibodies detected was significantly higher compared to the median antibody titer in the platelet units given to the group without antibodies detected (median [interquartile range]: 306 AU/ml [132, 400] vs. 96.1 AU/ml [30.6, 186], p = .027). Our study demonstrated a significant rate of passive transfer of SARS-CoV-2 spike protein IgG antibodies through platelet transfusions. Considering the volume of daily platelet transfusions, this is something all clinicians should be aware of.
Sections du résumé
BACKGROUND
Although over 5000 platelet transfusions occur daily in the United States, the presence of SARS-CoV-2 antibodies in platelet units is not commonly evaluated for. The effects of platelet transfusions with SARS-CoV-2 antibodies remain largely unknown. We evaluated single-donor (apheresis) platelet units for SARS-CoV-2 antibodies and determined if platelet transfusions passively transferred antibodies to seronegative recipients.
STUDY DESIGN AND METHODS
We conducted a retrospective analysis as part of a quality assurance initiative during February to March 2021 at a tertiary referral academic center in suburban New York. Platelet units and platelet recipients were evaluated for the presence of SARS-CoV-2 antibodies using the DiaSorin LIASON SARS-CoV-2 S1/S2 IgG assay. There were 47 platelet recipients eligible for study inclusion. The primary outcome was the presence of SARS-CoV-2 spike protein IgG antibodies in the recipient's blood after platelet transfusion.
RESULTS
Twenty-three patients received platelets with SARS-CoV-2 spike protein IgG antibodies; 13 recipients had detection of SARS-COV-2 antibodies (56.5%), and 10 recipients did not. The median antibody titer in the platelet units given to the group with passive antibodies detected was significantly higher compared to the median antibody titer in the platelet units given to the group without antibodies detected (median [interquartile range]: 306 AU/ml [132, 400] vs. 96.1 AU/ml [30.6, 186], p = .027).
CONCLUSIONS
Our study demonstrated a significant rate of passive transfer of SARS-CoV-2 spike protein IgG antibodies through platelet transfusions. Considering the volume of daily platelet transfusions, this is something all clinicians should be aware of.
Identifiants
pubmed: 35191047
doi: 10.1111/trf.16841
pmc: PMC9115505
doi:
Substances chimiques
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
764-769Informations de copyright
© 2022 AABB.
Références
JAMA. 2021 Mar 23;325(12):1185-1195
pubmed: 33635310
JAMA Intern Med. 2021 Apr 1;181(4):450-460
pubmed: 33231628
JAMA. 2020 Oct 27;324(16):1677-1679
pubmed: 32926078
Sci Transl Med. 2020 Sep 2;12(559):
pubmed: 32817357
JAMA Oncol. 2021 Jun 17;:
pubmed: 34137799
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316
N Engl J Med. 2021 May 20;384(20):1959-1961
pubmed: 33755375
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Transfusion. 2020 Mar;60 Suppl 2:S1-S9
pubmed: 32086817
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Transfusion. 2022 Apr;62(4):764-769
pubmed: 35191047